Glycoselect Investment opportunity - eiis 2021

GlycoSeLect opens Equity Raising Round for Irish Investors

Eligible Investors in the round can avail of tax relief up to 40% against Total Income under the Employment & Investment Incentive Scheme (EIIS) as part of their investment in qualifying Small and Medium Enterprises (SMEs).

This finance round will facilitate further investment and grants to develop our RPL technology in biopharmaceutical manufacturing, especially vaccine and cancer immunotherapy applications.

For more information on this investment opportunity, please contact our CEO, Robert Dunne, by email or Tel 01 2544164, Mobile 087 790265.

About GlycoSelect Ltd

GlycoSeLect Ltd develops innovative technologies for the analysis, characterisation and purification of biopharmaceuticals. These next-generation products are highly specific for glycan structures improving product development and improving the cost-efficiency of their manufacturing. GlycoSeLect specialises in the development of proteins based on recombinant prokaryotic lectins RPLs. Our RPL products advance efficient detection, analysis and selective isolation of glycosylated pharmaceutical products. GlycoSeLect’s family of RPLs products are associated with market-leading properties, including high affinity for glycan targets, high sensitivity of detection, high stability and robustness in process development.

More Stories